{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', 'The following COPD medications are permitted during the study, at the discretion of the', 'GSK Medical Monitor and/or Investigator:', 'Inhaled COPD maintenance medications (e.g. long acting bronchodilator', 'medications (i.e. LAMA, LABA) and long-acting bronchodilator combination', 'therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled steroid', 'combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)', 'Short courses of oral corticosteroids and/or antibiotics (including macrolides)', 'are permitted for the acute treatment of exacerbations of COPD and should not', 'exceed 21 days. This use must be recorded as an HCRU exacerbation event.', 'The following medications are prohibited from the screening visit until after completion', 'of the follow up visit:', 'Chronic use of macrolide antibiotics for the prevention of COPD exacerbations.', 'Examples of chronic use include daily or two-three times per week for at least', '3', 'months.', 'Oral or injectable CYP3A4 or BCRP substrates with narrow therapeutic index', '(CYP3A4 substrates include, but are not limited to, alfentanil, cyclosporine,', 'dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus,', 'tacrolimus, and theophylline; BCRP substrates include, but are not limited to,', 'topotecan.', 'Phosphodiesterase-4 inhibitors (e.g. roflumilast)', 'Broad spectrum phosphodiesterase inhibitors (e.g. theophylline)', 'GSK will not supply rescue medication. Participants may continue to use and should', 'obtain rescue medication(s) through via their usual route. The following rescue', 'medications may be used:', 'Short acting beta agonists (SABA)(e.g., albuterol/salbutamol)', 'Short acting muscarinic antagonists (SAMA)(e.g., ipratropium)', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', '30']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '31']\n\n###\n\n", "completion": "END"}